688166 博瑞医药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)4.4738.88012.38415.68812.380
总资产报酬率 ROA (%)2.0734.1786.28010.17010.457
投入资产回报率 ROIC (%)2.2184.5036.91011.2599.897

边际利润分析
销售毛利率 (%)55.29555.79463.01156.22754.927
营业利润率 (%)14.35316.12923.80324.60924.582
息税前利润/营业总收入 (%)17.20718.05124.77125.00924.960
净利润/营业总收入 (%)12.50214.70320.78322.57321.564

收益指标分析
经营活动净收益/利润总额(%)109.723105.52296.612102.12497.730
价值变动净收益/利润总额(%)-8.640-8.0840.2323.8921.877
营业外收支净额/利润总额(%)-0.096-0.7810.021-0.597-0.911

偿债能力分析
流动比率 (X)1.7151.9952.3881.7033.244
速动比率 (X)1.3891.6212.0431.3602.548
资产负债率 (%)53.84651.95451.90841.35121.623
带息债务/全部投入资本 (%)49.37247.83648.34135.207--
股东权益/带息债务 (%)98.670105.609105.323181.201584.603
股东权益/负债合计 (%)84.77390.60490.579136.663362.266
利息保障倍数 (X)5.9998.82025.71645.85341.597

营运能力分析
应收账款周转天数 (天)82.30789.395119.63694.1750.000
存货周转天数 (天)206.589215.752229.802157.5680.000